NCT03023384Unknown不适用
Feasibility Study of the Use of Intermediate Doses of Cytarabine Associated With Autologous Hematopoietic Stem Cells as Consolidation Treatment of Young Adults With Low- or Intermediate-risk de Novo Acute Myeloid Leukemia
International Consortium on Acute Leukemias6 个研究点 分布在 1 个国家目标入组 547 人开始时间: 2016年12月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 547
- 试验地点
- 6
- 主要终点
- Disease free survival
研究概览
简要总结
Create a network of institutions in developing countries that will perform AML diagnosis, risk classification, treatment, supportive care and follow-up evaluation according to a common protocol and will register data using common clinical research forms (CRFs) in a single database and available on the internet.
详细描述
- Compare overall survival and disease-free survival of patients with acute myeloid leukemia classified according the European LeukemiaNet treated in participating South American hospitals with the results reported in developed countries.
- Compare overall survival and disease-free survival of patients with AML low or intermediate risk treated with two cycles of cytarabine in intermediate dose versus one cytarabine cycle at the same dose followed by autologous SCT as consolidation. The risk will be established according to the classification of the European LeukemiaNet.
- Create a network of institutions in developing countries that will perform AML diagnosis, risk classification, treatment, supportive care and follow-up evaluation according to a common protocol and will register data using common clinical research forms (CRFs) in a single database and available on the internet
- Using National Reference Laboratories, provide cytogenetic and molecular methods for all institutions participating in the network, thus allowing rapid diagnosis and risk stratification of AML cases according to the European LeukemiaNet structure;
- Develop a method of assessing minimal residual disease based on flow cytometry adapted to local resources and capable of guiding therapeutic decisions;
- Determine the time interval between: a) diagnosis and risk group determination; b) the first cycle of consolidation chemotherapy and autologous hematopoietic stem cells infusion;
- Determine the frequency and etiologic agent of infections associated with treatment, the number and average duration of hospitalization due to episodes of neutropenia;
- Create a bank of samples of bone marrow from AML patients at different times of treatment;
- Determine the disease-free survival and the cumulative incidence rate of relapse and non-relapse mortality and compare them between chemotherapy alone and chemotherapy plus autologous SCT cohorts.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Acute myeloid leukemia (AML) diagnosis according to WHO criteria;
- •AML not treated previously, including: de novo AML or secondary to myelodysplastic syndromes;
- •Absence of t(15;17), or PML-RARA rearrangement and its variants (acute promyelocytic leukemia diagnosis);
- •Age greater than or equal to 18 years old or lower than or equal to 65 years old;
- •Functional status ECOG from 0 to 2;
- •Signed informed consent;
- •Ability to follow the protocol procedures;
- •Willingness to use birth control methods during the treatment until its conclusion;
- •Adequate renal and liver function:
- •Bilirubin ≤ 1.5x the upper limit of normality;
- •AST and ALT ≤ 2.5x the upper limit of normality;
- •Creatinine ≤ 2.5 mg/dL.
- •Suitable cardiac function: left ventricular ejection fraction ≥ 50%.
排除标准
- •Acute promyelocytic leukemia (APL) diagnosis according to WHO criteria;
- •Diagnosis of acute leukemia of ambiguous lineage, biphenotypic acute leukemia or undifferentiated acute leukemia, according to WHO criteria;
- •AML previously treated, except with hydroxyurea administration for cytoreduction;
- •Age greater than 65 years old or lower than 18 years old;
- •Functional status ECOG greater than 2;
- •Do not sign the informed consent;
- •Inability to follow the protocol procedures;
- •Be fertile female who are unwilling to take any birth control method during the treatment;
- •Hypersensitivity to any drug of the treatment protocol;
- •Positive serology for HIV;
- •Altered liver and renal function not related to the primary disease (AML):
- •Bilirubin > 1.5x the upper limit of normality
- •AST and ALT > the 2.5x upper limit of normality
- •Creatinine > 2.5 mg/dL
- •n) Altered cardiac function, with LVEF <50%
结局指标
主要结局
Disease free survival
时间窗: 2 years
Time from diagnosis until relapse
次要结局
- Overall survival(2 years)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
1 期
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast CancerAdvanced ER+, HER2-Negative Breast CancerNCT02338349Stemline Therapeutics, Inc.57
已完成
1 期
Glyburide Advantage in Malignant Edema and Stroke PilotIschemic StrokeNCT01268683Remedy Pharmaceuticals, Inc.10
已完成
不适用
Providing Accessible Diagnostic Evaluations and Psychoeducation for Autism Spectrum Disorder in Rural Southwest VirginiaAutism Spectrum DisorderNCT05822921Virginia Polytechnic Institute and State University21
已完成
不适用
The Development of a Patient Reported Outcomes Measure Committed to the Watch-and-wait Program for Rectal CancerRectal CancerNCT05040646Maastricht University Medical Center80
终止
不适用
Angel® Catheter Early Feasibility Clinical StudyDeep Vein ThrombosisPulmonary EmbolismVenous ThromboembolismNCT01847196BiO2 Medical6